The filing has substantive financial and operational content well above 150 words, so I will produce the full article.

Palvella Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Common shares outstanding: As of November 2, 2026, Palvella Therapeutics reported 14,618,457 shares of common stock outstanding.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Merger completed December 13, 2024: The company disclosed that it consummated a merger on that date, changing its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc.
  • Lead product candidate: The filing identifies QTORIN rapamycin as the company's lead product candidate, with QTORIN pitavastatin and research-stage programs also referenced.
  • Exchange listing: Common stock, $0.001 par value per share, is listed on NASDAQ:PVLA on the Nasdaq Global Market.
  • Not a shell company: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Palvella Therapeutics' Third-Quarter 2026 Filing: Corporate Background and Disclosures

Palvella Therapeutics, Inc. (NASDAQ:PVLA), headquartered at 353 W. Lancaster Ave, Suite 200, Wayne, Pennsylvania 19087, submitted its quarterly report covering the period ended September 30, 2026. The company disclosed that as of November 2, 2026, there were 14,618,457 shares of common stock outstanding. The report covers unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025, including balance sheets, statements of operations and comprehensive loss, statements of changes in preferred stock and stockholders' equity (deficit), and statements of cash flows.

According to the filing, the company's current form is the result of a merger completed on December 13, 2024, referred to in the document as the "Closing Date." On that date, Polo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Pieris Pharmaceuticals, Inc., merged with and into Legacy Palvella Therapeutics, Inc., a Delaware corporation, with Legacy Palvella continuing as a wholly owned subsidiary. Simultaneously, the company changed its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc. The filing notes that the merger was conducted pursuant to an Agreement and Plan of Merger dated July 23, 2024.

The company described its pipeline as focused on rare skin disease and vascular malformation indications. The filing identifies QTORIN rapamycin as the lead product candidate, with QTORIN pitavastatin and additional research-stage programs also listed among its development activities. The document contains forward-looking statements, which the company characterizes as subject to its cautionary language, including references to expectations regarding FDA regulatory approval of QTORIN rapamycin and, if approved, a subsequent commercial launch. The company holds Commission File Number 001-37471 and is incorporated in Nevada with an IRS Employer Identification Number of 30-0784346.

What Was Disclosed

Palvella Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 14,618,457 shares outstanding as of November 2, 2026, its smaller reporting company status, the December 2024 merger completing its name change from Pieris Pharmaceuticals, and its pipeline centered on QTORIN rapamycin.